Related Experiment Video
Updated: Mar 3, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
What is known about melatonin, chemotherapy and altered gene expression in breast cancer
Carlos Martínez-Campa1, Javier Menéndez-Menéndez1, Carolina Alonso-González1
1Department of Physiology and Pharmacology, School of Medicine, University of Cantabria and Research Institute Valdecilla, 39011 Santander, Spain.
Abstract:
Melatonin, synthesized in and released from the pineal gland, has been demonstrated by multiple in vivo and in vitro studies to have an oncostatic role in hormone-dependent tumors. Furthermore, several clinical trials point to melatonin as a promising adjuvant molecule to be considered for cancer treatment. In the past few years, evidence of a broader spectrum of action of melatonin as an antitumor agent has arisen; thus, melatonin appears to also have therapeutic effects in several types of hormone-independent cancer, including ovarian, leukemic, pancreatic, gastric and non-small cell lung carcinoma. In the present study, the latest findings regarding melatonin molecular actions when concomitantly administered with either radiotherapy or chemotherapy in cancer were reviewed, with a particular focus on hormone-dependent breast cancer. Finally, the present study discusses which direction should be followed in the next years to definitely clarify whether or not melatonin administration could protect against non-desirable effects (such as altered gene expression and post-translational protein modifications) caused by chemotherapy or radiotherapy treatments. As treatments move towards personalized medicine, comparative gene expression profiling with and without melatonin may be a powerful tool to better understand the antitumor effects of melatonin, the pineal gland hormone.
Insights
Melatonin, a pineal gland hormone, shows oncostatic effects against hormone-dependent and independent cancers. Further research is needed to clarify its protective role against chemotherapy and radiotherapy side effects.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Melatonin, synthesized by the pineal gland, exhibits oncostatic properties in hormone-dependent tumors.
- Clinical trials suggest melatonin's potential as an adjuvant cancer therapy.
- Emerging evidence indicates melatonin's efficacy in hormone-independent cancers like ovarian, leukemia, pancreatic, gastric, and non-small cell lung carcinoma.
Purpose of the Study:
- To review the latest findings on melatonin's molecular actions in conjunction with radiotherapy or chemotherapy.
- To focus on melatonin's role in hormone-dependent breast cancer treatment.
- To discuss future research directions for melatonin's protective effects against cancer treatment-induced side effects.
Main Methods:
- Literature review of in vivo and in vitro studies.
- Analysis of clinical trial data.
- Discussion of gene expression profiling for personalized medicine.
Main Results:
- Melatonin demonstrates an oncostatic role in hormone-dependent tumors.
- Melatonin shows therapeutic effects in various hormone-independent cancers.
- Melatonin's molecular actions with radiotherapy and chemotherapy are under investigation.
Conclusions:
- Melatonin is a promising adjuvant molecule for cancer treatment.
- Further research is required to elucidate melatonin's protective mechanisms against chemotherapy and radiotherapy side effects.
- Comparative gene expression profiling may enhance understanding of melatonin's antitumor effects in personalized medicine.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Cancer
Targeted Cancer Therapies
There are several types of targeted therapies against...
MicroRNAs
MicroRNAs

